Within the field of biochemistry, Bart van der Lelie has specialized in fundamental research, particularly in oncology and immunology. He began his career in the pharmaceutical industry, where he advanced to an executive position, with responsibilities including government relations, media and communications, pharmacoeconomics, reimbursements, and pricing policy. In his current role as director of Lysiac in Zeist (research, training, and consulting in healthcare), Bart van der Lelie focuses on policies regarding the financing of specialized care. Based on his experience in policy development and with an eye for diverse interests and the political context, he is committed to improving these policies and their implementation in practice. To this end, he collaborates with the government, hospitals, patient organizations, pharmaceutical companies, pharmacists, specialists, and other healthcare providers.